CNS Data From REZILIENT2 Show Intracranial and Systemic Activity in Challenging NSCLC Population
At the 2025 European Society for Medical Oncology (ESMO) Congress, Cullinan Therapeutics (NASDAQ:CGEM) and Taiho Oncology presented promising interim results for zipalertinib, their next-generation EGFR inhibitor. In patients with advanced non-small cell lung cancer (NSCLC) carrying EGFR mutations and active brain metastases, the Phase 2b REZILIENT2 trial demonstrated notable efficacy—shedding new light on a notoriously hard-to-treat group.
Key Efficacy Results Highlight Intracranial Benefit
The study enrolled 32 patients in the CNS involvement cohort. Of these, 21 had the difficult-to-treat EGFR exon 20 insertion mutations, while 13 carried other uncommon EGFR variants. These patients had a median of 2 prior therapy lines, underscoring a significant unmet medical need.
| Efficacy Endpoint | Results |
|---|---|
| Intracranial Objective Response Rate (RANO-BM, n=16) | 31.3% (1 complete response) |
| Intracranial Disease Control Rate | 68.8% |
| Median Intracranial Duration of Response | 8.1 months |
| Systemic Objective Response Rate (n=29) | 27.6% |
| Median Systemic Duration of Response | 7.6 months |
These early results show zipalertinib produced an intracranial objective response in roughly one-third of patients, with nearly 69% achieving disease control in the brain. The consistency between brain and systemic response rates hints at the drug’s potential reach—something rare in EGFR ex20ins NSCLC, particularly in those with central nervous system (CNS) metastases.
Safety Profile Remains Manageable Despite Aggressive Setting
Administered at 100 mg orally twice daily, zipalertinib was found to be well tolerated in the study population. No new safety signals were reported. Grade 3 or higher treatment-related adverse events occurred in 25% of patients. Notably, these included anemia (n=3) and interstitial lung disease (n=2). There was one death attributed to interstitial lung disease, highlighting a key risk to monitor as studies progress.
| Adverse Event (Grade 3+) | Patients Affected (n=32) |
|---|---|
| Anemia | 3 |
| Interstitial Lung Disease | 2 |
| Death Due to Interstitial Lung Disease | 1 |
Targeting a High-Need Subset: Clinical Relevance and Next Steps
The presence of baseline brain metastases in EGFR ex20ins NSCLC patients—ranging from 23% to 39% in prior reports—makes effective CNS therapies a significant gap in care. These early results from REZILIENT2 suggest zipalertinib may have potential to address that need. Importantly, both the objective response and duration data compare favorably to historical benchmarks for this challenging patient population.
Helena Yu, MD, of Memorial Sloan Kettering Cancer Center, underscored the finding: “In approximately one-third of patients exposed to zipalertinib, a decrease in CNS lesions was observed. These preliminary results suggest the potential for zipalertinib to treat these patients, warranting future investigation.”
Takeaway for Investors and Stakeholders
The positive preliminary efficacy and safety profile shown by zipalertinib in the REZILIENT2 CNS cohort not only advances Cullinan’s position in the EGFR NSCLC landscape but also points to real potential in a tough-to-treat segment. With ESMO as a stage, Cullinan and Taiho’s clinical progress will be watched closely—especially as additional data on duration of response, progression-free survival, and safety emerge.
While the candidate remains investigational and subject to future regulatory milestones, the emerging clinical evidence invites continued attention from those following both EGFR-targeted therapy innovation and the CGEM story.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI